Incyte Co. (NASDAQ:INCY) Shares Sold by Northwest & Ethical Investments L.P.

Northwest & Ethical Investments L.P. lowered its position in Incyte Co. (NASDAQ:INCY - Free Report) by 51.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 14,944 shares of the biopharmaceutical company's stock after selling 15,820 shares during the period. Northwest & Ethical Investments L.P.'s holdings in Incyte were worth $1,032,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Quintet Private Bank Europe S.A. acquired a new position in Incyte during the fourth quarter worth $26,000. Global X Japan Co. Ltd. lifted its stake in shares of Incyte by 144.7% in the fourth quarter. Global X Japan Co. Ltd. now owns 389 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 230 shares during the period. R Squared Ltd acquired a new position in Incyte during the fourth quarter worth about $30,000. Brooklyn Investment Group purchased a new position in Incyte in the third quarter valued at about $30,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Incyte during the 3rd quarter valued at approximately $33,000. Institutional investors and hedge funds own 96.97% of the company's stock.

Insider Buying and Selling at Incyte

In other news, EVP Barry P. Flannelly sold 19,807 shares of the business's stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $67.69, for a total value of $1,340,735.83. Following the completion of the sale, the executive vice president now directly owns 33,567 shares in the company, valued at approximately $2,272,150.23. The trade was a 37.11 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Sheila A. Denton sold 599 shares of Incyte stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $69.99, for a total transaction of $41,924.01. Following the completion of the transaction, the executive vice president now directly owns 25,848 shares of the company's stock, valued at approximately $1,809,101.52. This represents a 2.26 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 46,827 shares of company stock worth $3,322,618 in the last 90 days. 17.60% of the stock is owned by corporate insiders.

Remove Ads

Incyte Stock Down 0.8 %

NASDAQ:INCY traded down $0.51 during trading hours on Tuesday, hitting $62.27. The stock had a trading volume of 232,343 shares, compared to its average volume of 2,266,270. The business has a 50 day simple moving average of $70.42 and a two-hundred day simple moving average of $70.17. Incyte Co. has a 1-year low of $50.35 and a 1-year high of $83.95. The company has a current ratio of 1.97, a quick ratio of 1.94 and a debt-to-equity ratio of 0.01. The company has a market cap of $12.05 billion, a PE ratio of 230.67, a price-to-earnings-growth ratio of 0.41 and a beta of 0.76.

Incyte (NASDAQ:INCY - Get Free Report) last posted its quarterly earnings data on Monday, February 10th. The biopharmaceutical company reported $1.09 earnings per share for the quarter, missing analysts' consensus estimates of $1.57 by ($0.48). Incyte had a net margin of 0.77% and a return on equity of 0.05%. Analysts predict that Incyte Co. will post 4.86 EPS for the current year.

Analyst Ratings Changes

INCY has been the subject of several research analyst reports. Cantor Fitzgerald reaffirmed a "neutral" rating on shares of Incyte in a research note on Friday, January 10th. Morgan Stanley dropped their price target on Incyte from $69.00 to $65.00 and set an "equal weight" rating for the company in a research report on Monday. StockNews.com cut Incyte from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, February 12th. Royal Bank of Canada decreased their price target on shares of Incyte from $70.00 to $68.00 and set a "sector perform" rating on the stock in a research note on Tuesday, February 11th. Finally, JMP Securities reaffirmed a "market perform" rating on shares of Incyte in a research note on Tuesday, February 11th. One investment analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, Incyte has a consensus rating of "Hold" and an average target price of $74.88.

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.